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Objectives   The number of dinucleotide repeats (GT)n modulate expression of heme oxygenase 1 (HMOX1), a 
stress response gene. Multiple repeats might affect chronic obstructive pulmonary disease (COPD) susceptibility. 
We aimed to investigate the association of this polymorphism with COPD and its interaction with occupational 
exposures (vapor, gas, dust, or fumes).
Methods   This population-based cross-sectional study included 4703 Danes, aged 45–84 years. HMOX1 (GT)n was 
genotyped and grouped as short: ≤26, medium: 27–32 and long: ≥33 alleles. COPD was defined by the lower limit 
of normal (2.5th FEV1/FVC and FEV1 centiles). Occupational exposure was defined as ever exposed to vapor, gas, 
dust, or fume in expert-selected jobs. Associations were analyzed by adjusted mixed logistic regression.
Results   The population included 6% with COPD, 48% who had smoked ≥10 pack-years, and 46% with occupa-
tional exposure. HMOX1 was genotyped in 4423 participants. The adjusted odds ratio (OR) for the association 
between HMOX1 long allele and COPD was 1.75 [95% confidence interval (CI) 1.18–2.60]. An interaction was 
evident between HMOX1 long allele and occupational exposure, OR 2.38 (95% CI 1.04–5.46), versus HMOX1 
short/medium without exposure. Analyses were replicated in another cohort, aged 20–44 years, N=1168, includ-
ing 3% with COPD, 25% who had smoked ≥10 pack-years and 20% with occupational exposure. No associations 
were seen between COPD and HMOX1 long allele here.
Conclusions   Long alleles in HMOX1 alone and in interaction with occupational exposure seem to be associated 
with COPD. Failure to replicate data may be due to premature age for COPD development and low occupational 
exposure prevalence. We propose this long allele may be a genetic contributor to the COPD pathogenesis.
Key terms   COPD; Denmark; dust exposure; gas exposure; gene-by-occupational interaction; genetic effect; 
HMOX1; lung function; occupational exposure; rs3074372; vapor exposure.
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Chronic obstructive pulmonary disease (COPD) is a 
common and complex disease with a genetic contribu-
tion (1). The most well-established risk polymorphisms 
are single-nucleotide polymorphisms (SNP) in the 
SERPINA gene causing alpha-1-antitrypsin deficiencies 
(2, 3).  However, only a few percent of COPD cases can 
be explained by the presently identified genetic variants. 
Further genetic studies in COPD are therefore needed to 
identify new genetic variants in order to establish new 
molecular targets for primary prevention, diagnosis, and 
treatment (4, 5).
Heme oxygenase 1 (HMOX1) is an anti-oxidant 
and anti-inflammatory heme-degrading enzyme and the 
gene is known as a cytoprotective stress response gene 
(6–8). A dinucleotide repeat (GT)n sequence in the 5’ of 
the promoter region of the HMOX1 gene (rs3074372) 
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modulates gene expression. A long allele (many repeats) 
has been shown to reduce enzyme activity and associ-
ate with various diseases (8, 9). Several studies have 
previously discussed whether this polymorphism affects 
COPD and impairs lung function yet with divergent 
outcomes and conclusions (4).
The main risk factor for COPD is smoking, but 
several occupational exposures are causally related to 
COPD (10). Furthermore, a genome-wide interaction 
study of gene-by-occupational exposure has recently 
identified new genetic variants associated with the 
level of forced expiratory volume in the first second 
of expiration (FEV1), where seven single nucleotide 
polymorphisms interacted with one of the occupational 
exposures (11).
In a Danish population-based cohort of 45–84-year-
old participants, we previously suggested occupational 
exposure to vapor, gas, dust, or fume (VGDF) is associ-
ated with COPD (12). In this paper, we hypothesise that 
the effect of a genetic variant may be different in occu-
pationally exposed compared to smoking subjects. This 
is due to a lower inflammatory effect on lungs by occu-
pational exposure than by individual smoking. Thus, the 
genetic effect may be more pronounced in unexposed 
subjects or less occupational exposed subjects. 
The aim of this cross-sectional study was first to 
investigate the association of HMOX1 promoter poly-
morphism of (GT)n repeats with COPD and second to 
investigate the presence of a possible gene-by-environ-
ment interaction with VGDF and smoking.
Methods
Population
The study population is based on the Danish North Jut-
land COPD Prevention Study (NCPS), the primary aims 
of which were to estimate the prevalence of COPD in the 
Danish population aged 45–84 years and to determine the 
prevalence of cases without appropriate medical treat-
ment (13). General practitioners (GP) from two former 
counties in northern Jutland enrolled participants in the 
period October 2004 – September 2006. Patients listed 
with participating GP were selected randomly from the 
Danish Civil Registration System based on the expected 
prevalence of COPD in sex-specific 10-year age groups. 
Thus, the sample a priori had an overweight of elderly 
participants and men. Data were gathered from self-
administered questionnaires (on education, work, family 
history of lung disease, medical information, smoking and 
alcohol habits, asthma, and allergy) and medical exami-
nations including spirometry and blood samples. The 
response rate in the study was 36% (13). We studied occu-
pational VGDF exposure in this cohort and included 4717 
participants (12). All participants of non-Scandinavian 
descent were identified through their names and excluded 
in the genetic part of the study (N=14).
Lung function and COPD definition
The GPs obtained measures of FEV1 and forced vital 
capacity (FVC) by spirometry. All healthcare staff per-
forming spirometry participated in a one-day training 
module before entering the study, and all spirometers 
were calibrated twice every year. A bronchodilator was 
not administered to all participants; hence, pre-broncho-
dilator spirometry was used consistently throughout the 
study. The lower limit of normal (LLN) approach was 
used to define COPD (14) in a screening setting based 
on the FEV1/FVC 2.5th centile (z-score = -1.96) (15). 
COPD severity was assessed using a detailed grading 
system based on LLN according to FEV1. To distinguish 
subjects with at least moderate airway obstruction, we 
added the recommended criterion of LLN for FEV1 of a 
z-score = -2.0 (rounded 2.5th centile) (16). As reference 
population, we used the Global Lung Function 2012 
Equations (15) in the “GLI-2012 Desktop Software for 
Large Data Sets version 1.3.4 build 3” (17).
Occupational exposure
The duration of occupational exposure (years in occupa-
tions with exposure) was used as a proxy for cumulative 
occupational exposure and assessed based on a self-admin-
istered questionnaire of past and present occupations. 
The lifetime occupational VGDF exposure was divided 
into: organic dust, inorganic dust, vapor, and gas/fume. 
To improve the validity of the self-reported exposure 
information, we restricted such information as to a priori 
expert-selected jobs with known occupational exposures 
to VGDF using the Danish adapted version of the Inter-
national Standard Classification of Occupations, revision 
1988 (DISCO-88) (18) (supplementary material www.
sjweh.fi/show_abstract.php?abstract_id=3846, table 
S1). The expert-selected jobs with occupational exposure 
included 72 of 372 DISCO-88 codes. VGDF exposure was 
originally assessed in four levels: never, low (<5 years), 
medium (5–14 years), and high (≥15 years) occupational 
lifetime exposure. VGDF was used as a dichotomized 
never versus ever (low/medium/high) exposure variable 
due to power issues when the genetic variant was included.
Genotyping
The repeat polymorphism in the promoter region in 
HMOX1  (rs3074372, GRCh38:22:35,381,066-
35,394,213) was amplified by polymerase chain reac-
tion (PCR) using a fluorescent-labelled sense primer 
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(5’-AGAGCCTGCAGCTTCTCAGA-3’) and an unla-
beled antisense primer (5’-ACAAAGTCTGGCCATAG-
GAC-3’) covering the (GT)n repeats (19–21). The PCR 
products were subsequently genotyped according to size 
using an ABI 3730XL DNA Analyzer (Thermo Fischer 
Scientific, Waltham, MA, USA) using GeneMarker® 
software (SoftGenetics, State College, PA, USA). The 
output of each allele GT repeats was blinded and calcu-
lated in respect to an internal size standard where 128 
base pairs equals 30 GT repeats. Of the blood samples, 
31 were missing, 48 were insufficient (eg, serum) and 201 
failed in the HMOX1 analysis, which resulted in 4423 
participants with a valid HMOX1 genotype. The cut-off 
of the GT repeats was defined as short (S): ≤26; medium 
(M): 27−32; and long (L): ≥33 GT repeats (21–23). The 
individual S/M/L genotype was grouped according to 
an L-dominant genetic model as HMOX1 L- (S/S, S/M, 
M/M) and HMOX1 L+ (S/L, M/L, L/L) groups.
Smoking
Cumulated smoking estimated as smoked pack-years 
was categorized into three levels, namely, <10, 10–20, 
and >20 pack-years. Different types of smoking were 
converted into number of smoked cigarettes as follows: 
one cheroot=three cigarettes; one cigar=four cigarettes; 
one pipe bowl=three cigarettes; and a package of pipe 
tobacco (50 gram)=17 pipe bowls.
Statistics
Statistical analyses were conducted in Stata 14.2 (Stata-
Corp LP, College Station, TX, USA). The significance 
level was set at 5%. The 95% confidence interval (CI) 
was calculated using a normal approximation. The chi-
square test for categorical variables was used to assess 
differences between sub-groups of the study population. 
Status of Hardy-Weinberg Equilibrium (HWE) was per-
formed among non-COPD participants according to their 
HMOX1 S/M/L genotype. Associations of the HMOX1 
polymorphism with COPD were analyzed in univariate 
and mixed random effect logistic regression models (24) 
with GP practice as a random variable. Likelihood-ratio 
tests were performed for possible gene-by-environment 
interactions of occupational exposure and smoking, 
respectively. The odds ratio (OR) from the mixed regres-
sion model was adjusted for pack-year, sex, occupational 
exposure, and age as fixed effects. Additionally, analyses 
were presented in a separate table as recommended by 
Knol et al (25), including post-estimation of any additive 
interaction. We used five regression models to compare 
no COPD with each level of COPD severity. Sensitiv-
ity analyses were performed by restriction according 
to (i) never smokers; (ii) no prior self-reported asthma; 
(iii) different dichotomization of occupational VGDF 
exposure: never/low versus medium/high and never/low/
medium versus high occupational exposure; and (iv) dif-
ferent HMOX1 L± cut-offs according to (GT)n promoter 
repeats (N=31, 32, 34 and 35). The arguments for these 
analyses were: (a) to emphasize the a priori assumption 
of a diverse effect of HMOX1 polymorphism between a 
large smoking exposure and a low occupational expo-
sure, by excluding the major risk factor of COPD, (b) to 
avoid the predisposing effect of asthma to COPD in the 
analysis (26, 27), (c) to investigate the effect of different 
levels of occupational exposures in the model, and (d) 
to analyze the effect of different cut-offs of the HMOX1 
repeat polymorphism due to no clear argument for the 
used HMOX1 cut-offs in the literature.
Ethics
The NCPS study was performed in accordance with 
the Helsinki Declaration and approved by the Danish 
Scientific Ethics Committee (VN2003/62) and the Dan-
ish Data Protection Agency (2007-41-1576). Written 
informed consent was obtained from all participants. 
The Danish Scientific Ethics Committee also approved 
blood usage in the genetic analyses (N-20130038).
Replication study
The analyses were replicated in the Danish RAV (risk 
factors for asthma among adults) cohort (28), which is 
based on the European Community Respiratory Health 
Survey (ECHRS) protocol (29). Briefly, the RAV cohort, 
which was designed primarily to identify risk factors for 
asthma, comprised 20–44-year-old subjects (N=1191) of 
whom 44% were males, 54% were never smokers, and 
30% had ever self-reported asthma. Thirty-four COPD 
cases were present (3%). In addition, data on lung func-
tion, occupational history of the latest ten jobs and blood 
samples were available. Participants were excluded if 
they were born outside Scandinavia (N=23); 86 blood 
samples failed in the HMOX1 analysis. Hence, 1082 
participants with a valid HMOX1 genotype were avail-
able for analysis.
Results
The study population is characterized in table 1 according 
to genotype and stratified by presence of the long allele 
(L± GT33 repeats). The population included 6% with 
COPD, 48% who had smoked ≥10 pack-years, and 46% 
with occupational VGDF exposure. Only the prevalence 
of asthma and COPD differed between the L- and the L+ 
genotypes. The (GT)n allelic distribution of the longest 
allele is shown in figure 1. An HMOX1 L+ genotype was 
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present in 10.6%. HMOX1 L+ in non-COPD partici-
pants fulfilled the criteria of being in HWE, P=0.24. The 
crude association between COPD and a long (GT)n allele 
(HMOX1 L+) was OR 1.66 (95% CI 1.17-2.34) while 
the adjusted OR slightly increased OR 1.75 (95% CI 
1.18–2.60) (table 2). Additionally increased OR of COPD 
was observed when having HMOX1 L+ and occupational 
VGDF exposure together in a gene-by-environment 
interaction, OR 2.38 (95% CI 1.04–5.46), versus HMOX1 
S+M and no exposure. There seemed to be a positive 
additive interaction as well as a positive interaction on 
the multiplicative scale between HMOX1 L+ and VGDF 
exposure (table 3). As the estimated OR exceeded the 
expected OR, we additionally analyzed the data without 
any adjustments (supplementary table S2.A) and without 
the pack-year adjustment (supplementary table S2.B); 
these estimated OR were 2.75 (95% CI 1.30–5.80) and 
2.62 (95% CI 1.15–5.95), respectively.
No significant interaction was seen between the 
HMOX1 L+ and smoking: HMOX1 and >20 pack-
years OR 1.13 (95% CI 0.38–3.35), likelihood-ratio test 
P=0.98 (supplementary table S3).
Sensitivity analyses: (i) Restricted to never smokers, 
the crude association between COPD and HMOX1 L+ 
was increased. Excluding sex and age variables in the 
model among never smokers barely changed the asso-
ciation between COPD and HMOX1 L+, OR 2.39 (95% 
CI 0.76–7.55); however, the impact of VGDF exposure 
seemed to decrease, OR 3.35 (95% CI 1.24–9.05). (ii) 
Among non-asthmatics, the crude association between 
COPD and HMOX1 L+ was similar to that of all partici-
pants, OR 1.69 (95% CI 1.07–2.28). (iii) Changing the 
occupational exposure to never/low versus medium/high 
slightly increased the effect of the VGDF and HMOX1 
interaction. Comparing with the high exposure the esti-
mate decreased into insignificance. (iv) Different genetic 
Table 1. Characteristics of the study participants N=4423 a strati-
fied by HMOX1 ±long GT allele genotype. [COPD=chronic obstructive 
pulmonary disease; L- =no-polymorphism, <33 GT promoter repeats; 
L+ =(GT)n promoter repeat polymorphism, including ≥33 GT repeats; 
S=small ≤26 GT repeats; M=medium 27−32 GT repeats; L=long ≥33 
GT repeats; VGDF=occupational vapor, gas, dust, or fumes]. Bold indi-
cates statistically significant, P<0.05.
HMOX1 GT33 promoter repeats
COPD b L- genotype L+ genotype P 
value
N N % N %
HMOX1 genotype L- 3956 89 467 11
S/S 37 534 14 - -
S/M 100 1875 47 - -
M/M 86 1547 39 - -
HMOX1 genotypeb L+ 
S/L 16 - - 172 37
M/L 26 - - 289 62
L/L 0 - - 6 1
Sex
Female 73 1369 35 155 33
Male 192 2587 65 312 67 0.5
Age years
45−54 29 802 20 96 21
55−64 46 930 24 119 25
65−74 122 1485 38 174 37
75−84 68 739 19 78 17 0.7
Smoked pack-years (N=4093)
0<10 38 1785 49 197 46
10−20 25 483 13 72 17
>20 177 1395 38 161 37 0.1
VGDF exposure (N=4196)
No 106 1951 52 236 54
Low 19 317 8 32 7
Medium 34 344 9 53 12
High 90 1143 30 120 27 0.1
Ever asthma (N=4365)
No 148 3505 90 391 85
Yes 110 401 10 68 15 <0.01
COPD b (N=4406)
No 3718 94 423 91
Yes 265 223 6 42 9 <0.01
a N=280 missing/invalid HMOX1 genotypes.
b Defined by the lower limit of normal. 
Figure 1. The (GT)n allelic distribution 
of the longest allele among the 4423 
valid HMOX1 analyses in the North 
Jutland COPD Prevention Study.  The 
vertical dotted line divides the group 
into L- and L+ genotype according 
to an L-dominant genetic model. 
[S=small, ≤26 GT repeats; M=medium, 
27−32 GT repeats; L=large, ≥33 GT 
repeats.]
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HMOX1 L cut-offs were analyzed. The main cut-off was 
33 GT repeats, as shown in figure 1 by the dotted line. 
Of all the different cut-off models, only the lowest cut-
off L+31 was insignificant according to HMOX1. All 
other models were similar to the used model with 33 
GT repeats (L+).
Analysis according to COPD severity and HMOX1 
L+ revealed no associations or indication of a trend 
(data not shown).
Replication study
In the RAV cohort, 19% had occupational VGDF expo-
sure. The median age was 35 (standard deviation 7.0) 
years and 3% (N=32) had COPD. The (GT)n allelic 
distribution in the RAV cohort across genotypes (L-: S/S 
15%, S/M 47%, M/M 38% and L+: S/L 34%, M/L 63%, 
L/L 4%) was similar to the NCPS distribution shown in 
table 1. HMOX1 L+ in non-COPD participants fulfilled 
Table 2.  Associations between chronic obstructive pulmonary disease (COPD) and Heme oxygenase 1 (HMOX1) polymorphism with and without the 
occupational vapor, gas, dust or fume (VGDF) exposure interaction in the North Jutland COPD Prevention Study (NCPS) and RAV (risk factors for asthma 
among adults cohort) studies. [CI=confidence interval; L- =no-polymorphism, <33 (GT) promoter repeats; L+ =(GT)n promoter repeat polymorphism, 
including ≥33 (GT) repeats; OR=odds ratio; NA=not available, too few observations; - =not included in the model]. Bold indicates statistically 
significant, P<0.05.
NCPS (all, N=3871) NCPS (never smokers, N=1385) RAV replication study (N=986)
Adjusted OR a Adjusted OR a + interaction Adjusted OR a Adjusted OR a
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
HMOX1
L- 1 1 1 1
L+ 1.75 1.18–2.60 1.06 0.55–2.06 2.41 0.75–7.78 0.23 0.03–1.75
Pack–years of smoking
<10 1 1 - - 1
10–20 2.69 1.57–4.60 2.70 1.58–4.61 - - 2.59 0.95–7.04
>20 7.64 5.13–11.39 7.67 5.15–11.42 - - 3.60 1.29–10.00
Sex
Female 1 1 1 1
Male 0.54 0.37–0.78 0.55 0.38–0.79 0.32 0.12–0.88 1.68 0.73–3.86
Age, RAV replication study
20–25 - - - - - - 1
26–30 - - - - - - 1.02 0.26–3.99
31–35 - - - - - - 0.50 0.11–2.32
36–40 - - - - - - 0.89 0.24–3.29
41–47 - - - - - - 0.86 0.23–3.29
Age, NCPS study population
45–54 1 1 1
55–64 1.29 0.76–2.17 1.32 0.78–2.23 1.16 0.25–5.46 - -
65–74 2.26 1.41–3.60 2.29 1.43–3.66 1.63 0.40–6.61 - -
75–84 2.33 1.39–3.91 2.38 1.42–3.99 2.66 0.59–12.02 - -
VGDF
Never 1 1 1 1
Ever 1.38 1.01–1.88 1.21 0.87–1.69 5.12 1.70–15.46 1.73 0.73–4.09
VGDF and HMOX1 interaction
Never/L- - - 1 NA NA
Ever/L+ - - 2.38 1.04–5.46 NA NA NA NA
a Adjusted for pack-years of smoking, sex, age, VGDF and additional non-reported adjustments including general practitioner practice in a mixed random effect lo-
gistic regression.  
Table 3. Interaction between HMOX1 L± genotype and VGDF exposure on the risk of chronic obstructive pulmonary disease (COPD), adjusted 
for pack-years, sex, age and general practitioner practice (N=3871). [HMOX1=Heme oxygenase 1 gene; L-= no-polymorphism, <33 (GT) pro-
moter repeats; L+= (GT)n promoter repeat polymorphism, including ≥33 (GT) repeats; OR=odds ratio; RERI= relative excess risk due to interaction; 
VGDF=vapour, gas, dust or fume occupational exposure]. Bold indicates statistically significant, P<0.05. Note: Measure of interaction on additive 
scale: RERIOR (95% CI) = 1.79 (0.18−3.40); P=0.03. Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.38 (1.04−5.46); P=0.04.
HMOX1 genotype according to L± HMOX1 OR within 
VGDF strataNo long HMOX1 promoter alleles (L-) ≥1 long HMOX1 promoter allele (L+)
N COPD/
non-COPD
OR 95% CI P-value N COPD/
non-COPD
OR 95% CI P-value OR 95% CI P-value
VGDF
Never 87/1722 1.00 11/209 1.06 0.55–2.06 0.86 1.07 0.55–2.09 0.85
Ever 104/1556 1.21 0.87–1.69 0.25 23/159 3.07 1.81–5.20 <0.01 2.51 1.51–4.15 <0.01
VGDF OR within 
HMOX1 strata
1.22 0.87–1.71 0.24 3.30 1.33–8.19 0.01
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the criteria of being in HWE, P=0.74. The estimates are 
included in table 2, showing no replication of the genetic 
effect and no replication of the HMOX1−VGDF interac-
tion associated with COPD. Later, we additionally used 
asthma as outcome in the analysis of the younger RAV 
cohort since asthma predisposes to COPD. We found an 
insignificant, positive association with HMOX1 L+, OR 
1.15 (95% CI 0.76–1.74).
Discussion
We found an increased risk of COPD in subjects car-
rying ≥1 long GT allele in the HMOX1 alone and in 
a gene-environmental interaction with occupational 
VGDF exposure. The combined COPD effect exceeded 
the effect of occupational VGDF exposure alone, sug-
gesting that the association of the long allele of HMOX1 
with occupational VGDF exposure is stronger than the 
association of HMOX1 with smoking between which 
no significant interaction was observed. The results 
among never smokers tend to support the association 
between COPD and HMOX1 L+ (similar OR) and 
VGDF (increased OR) compared to the main model 
without gene-environmental interaction (table 2). As 
asthma predisposes to COPD development (26, 27), 
analyses performed among non-asthmatics might under-
estimate the true association. On the other hand, due to 
the same reason, inclusion of asthmatics might also have 
overestimated the association. Thus, the best epidemio-
logical estimate probably lies somewhere between the 
estimates obtained with models including and excluding 
asthmatics. The insignificance occurred when changing 
the occupational exposure to never/low/medium versus 
high exposure could be explained by low power and/or 
a healthy worker effect (supplementary table S4).
We applied the commonly used cut-off of L+ ≥33 
GT repeats for the HMOX1 promotor polymorphism. 
However, the model was slightly sensitive for change 
in HMOX1 L cut-offs between L32 and L35.
Comparable studies in European populations regard-
ing COPD and the (GT)n repeats have been studied. Mato-
kanovic et al (30) found no association between COPD 
and the length of the GT repeat polymorphism in a small 
(N=225) Croatian population. In that study, COPD was 
defined by the GOLD criteria, and the study used cut-offs 
in GT repeats (S≤25, M 26-31, L≥32) that were slightly 
different from ours. Although, Hersh et al (20) found no 
association between COPD and the previously used S, 
M, and L groups of GT repeats in HMOX1, they found 
associations with the two most common single-number 
of repeats (GT repeats 30 and 31) in two different study 
populations (case−control and pedigree family-based). 
These populations included <1000 participants each.
Guenegou et al (21) studied associations of GT 
repeats in HMOX1 and 8-year lung function decline in 
749 French participants in the European Community 
Respiratory Health Survey. L+ allele carriers had a 
more rapid decline in FEV1/FVC, and this decline was 
significantly steeper among heavy smokers. Siedlin-
ski et al (22) later replicated these results in a Dutch 
general population (N=1390). The FEV1 decline was 
significantly increased in the M/L+L/L genotype, and 
the decline remained significant in restricted analyses 
in ever and heavy smokers (22).
In table 3, VGDF+ exposure was stratified within 
the HMOX1 L± strata, and the estimated OR was 3.30 
(95% CI 1.33−8.19) in the HMOX1 L+ exposure group. 
As smoked pack-years were equally distributed between 
HMOX1 L± (table 1) and the expected OR according to 
table 3 would be OR 2.90 (= 3.07/1.06) and lower than 
the estimated OR, we interpret this stratified estimate 
as an indication of some interaction between HMOX1 
L+ and smoking. To validate this interpretation, we 
analyzed the data without any adjustments (supplemen-
tary table S2.A) and without the pack-year adjustment 
(supplementary table S2.B); the calculated estimated 
OR were 2.75 (95% CI 1.30−5.80) and 2.62 (95% CI 
1.15–5.95), respectively. Since these OR were more 
in line with the expected values, the data suggest that 
HMOX1 L+ interacts to a smaller extent with smoking 
than with VGDF in a gene-by-environmental pathway 
with COPD, see supplementary table S3; interaction 
between HMOX1 and >20 pack-years OR 1.13 (95% 
CI 0.38–3.35). We interpret this as the intense smoking 
exposure is less modified by the presence of HMOX1 
L+, than the low-dose environmental exposures, eg, 
occupational exposure. Both additive and multiplica-
tive statistical interactions of VGDF and HMOX1 were 
present (table 3). The additive estimate of interaction 
suggests the presence of a mechanistic interaction as a 
sufficient cause interaction, equally the relative excess 
risk due to interaction (RERI)>1. Although, RERI is 
not significant as the lower 95% CI are <1. Neverthe-
less, the biological role of HMOX1 appears rather well 
documented (31, 32), suggesting that our finding does 
represent a biological effect.
Two studies combined the promoter GT repeats in 
HMOX1 and lung function with other exposures of 
ozone (33) and PM10 (particulate matter <10 µm) (23). 
These studies point in the same direction as our study 
despite different L cut-offs, exposures and outcomes. 
Thus indicative of, a HMOX1 promoter polymorphism 
association with exogenous exposure.
Strengths and limitations
The strengths of the present study are its size, the expert-
validated occupational exposures, and that genotyping 
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was validated in a blinded setting. Ethnic variability 
was restricted although non-differential misclassification 
might occur. Another limitation is that we did not include 
other genetic risk factors that might affect the association 
with the VGDF exposure and HMOX1 interaction.
Of the samples in the HMOX1 analysis, 201 (NCPS) 
and 86 (RAV) failed, however, we deem the analytical 
success rate (95%) to be acceptable. The failed HMOX1 
data not included in the analysis were equally distributed 
among plates. Among the study participants, there were 
more young women and fewer participants in the oldest 
group than among non-responders. This might introduce 
an age-dependent healthier study population, which 
would tend to underestimate the associations. The use 
of a spirometrically defined outcome of COPD implies 
that some COPD patients with compliance difficulties 
might have been excluded from the analysis, resulting 
in biased associations. Possible information bias of 
occupational VGDF exposure was reduced by using 
independent, specialist-assessed exposure based on job 
titles. The external study validity is considered good 
in a Western world setting with a similar occupational 
distribution and a Northern European genetic structure.
Replication
Although the distribution of HMOX1 genotypes was 
similar in RAV and NCPS, no associations were seen in 
the RAV cohort. We attribute this to the smaller study 
size and lower VGDF exposure in RAV and the short 
time period for development of COPD in this cohort. 
A priori, we assumed that the HMOX1 repeat polymor-
phism would be associated with COPD and not interact 
with occupational exposure. However, in the younger 
RAV cohort with less occupational exposure, HMOX1 
L+ was inversely associated with COPD, and our data 
regrettably lacked power to analyze for the combined 
exposure. Although insignificant, the finding according 
to asthma might suggest that in this young cohort, an 
association could be relevant between HMOX1 L+ and 
obstructive lung disease.
To our knowledge, this is the largest population-
based study analyzing promoter repeats in HMOX1. 
However, our findings would benefit from other repli-
cation studies with more VGDF exposure in an older 
cohort than the present study.
The intension of social threshold values as a tool for 
primary prevention is that workers doing their job will 
not be at increased risk of disease from occupational 
exposure, not even if they are genetically susceptible. 
The data may suggest that the actual threshold values 
ought to be lowered to meet the intension of the current 
labor market regulations. Moreover, the genetic marker 
may inform secondary prevention measures in workers 
with lung symptoms exposed to VGDF. Subjects with 
long GT alleles in HMOX1 may be more susceptible and 
would benefit from shifting to other work tasks with less 
VGDF exposure.
Concluding remarks
The present data support an association between subjects 
with a long GT allele in HMOX1 and COPD. A long GT 
allele in HMOX1 seems furthermore to interact with 
occupational VGDF exposure in a gene-by-occupational 
setting. We propose that the positive association with a 
long GT allele in HMOX1 may be a new genetic con-
tributor to the pathogenesis of COPD. Additionally, the 
HMOX1 interaction with occupational VGDF exposure 
provide an argument for VGDF exposure level regula-
tion in respect of primary and secondary prevention.
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